Cepheid (CPHD) Tops Q1 EPS by 17c

Cepheid (NASDAQ: CPHD) reported Q1 EPS of $0.01, $0.17 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $132.6 million versus the consensus estimate of $125.5 million.

Excluding stock-based compensation expense, amortization of debt discount and transaction costs, and amortization of purchased intangible assets, non-GAAP net income for the first quarter of 2015 was $12.4 million, or $0.17 per share. This compares to a non-GAAP net loss of $(0.6) million, or $(0.01) per share, in the first quarter of 2014.

"Momentum continues to build across our business, with strong execution on our test menu, geographic expansion, and market extension programs all contributing to record first quarter revenue," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "In the last 12 months, Cepheid has added eight tests to the international Xpert menu, including the milestone HIV Viral Load, HIV Qualitative and HCV Viral Load tests. Regardless of size, many of our international customers now have the capability to offer a broad molecular menu of HAI, critical infectious disease, sexual health and virology tests on a single accurate, efficient, scalable, and cost-effective platform."

For earnings history and earnings-related data on Cepheid (CPHD) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• AT&T (T) beats earnings estimates in Q1 but revenue falls short, shares climb
• Bok Financial Corp (BOKF) Misses Q1 EPS by 27c